Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Nov 15, 2023; 14(11): 1659-1671
Published online Nov 15, 2023. doi: 10.4239/wjd.v14.i11.1659
Molecular targets and mechanisms of Jiawei Jiaotai Pill on diabetic cardiomyopathy based on network pharmacology
Yu-Juan Wang, Yan-Li Wang, Xiao-Fan Jiang, Juan-E Li
Yu-Juan Wang, Department of Otolaryngology, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaaxi Province, China
Yan-Li Wang, Department of Pediatrics, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, Xinjiang Uygur Autonomous Region, China
Xiao-Fan Jiang, Juan-E Li, Department of Chinese Medicine, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaaxi Province, China
Author contributions: Wang YJ and Wang YL contributed to the literature search; Jiang XF performed the data acquisition and statistical analysis; Li JE contributed to the manuscript preparation and editing; All authors have approved the final manual.
Supported by Natural Science Basic Research Plan in the Shaanxi Province of China, No. 2021JM-549, The Plan Project of Shaanxi Provincial Administration of Traditional Chinese Medicine, No. 2021-ZZ-JC011; and The Second Youth Science and Technology Talents Project of Shaanxi Provincial Administration of Traditional Chinese Medicine, No. 2023-ZQNY-017.
Institutional review board statement: The data used in this study are all public data from public databases, and do not involve human or animals data, so there is no need for ethical review.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: The data used for this study can be obtained from the corresponding authors at lizhuan-1980@126.com.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Juan-E Li, MD, Associate Chief Physician, Department of Chinese Medicine, Shaanxi Provincial People’s Hospital, No. 256 Youyi West Road, Beilin District, Xi’an 710068, Shaaxi Province, China. lizhuan-1980@126.com
Received: June 20, 2023
Peer-review started: June 20, 2023
First decision: July 7, 2023
Revised: July 12, 2023
Accepted: October 8, 2023
Article in press: October 8, 2023
Published online: November 15, 2023
Processing time: 146 Days and 22.7 Hours
Abstract
BACKGROUND

Jiawei Jiaotai Pill is commonly used in clinical practice to reduce apoptosis, increase insulin secretion, and improve blood glucose tolerance. However, its mechanism of action in the treatment of diabetic cardiomyopathy (DCM) remains unclear, hindering research efforts aimed at developing drugs specifically for the treatment of DCM.

AIM

To explore the pharmacodynamic basis and molecular mechanism of Jiawei Jiaotai Pill in DCM treatment.

METHODS

We explored various databases and software, including the Traditional Chinese Medicine Systems Pharmacology Database, Uniport, PubChem, GenCards, String, and Cytoscape, to identify the active components and targets of Jiawei Jiaotai Pill, and the disease targets in DCM. Protein-protein interaction network, gene ontology, and Kyoto Encyclopedia of Genes and Genomes analyses were used to determine the mechanism of action of Jiawei Jiaotai Pill in treating DCM. Molecular docking of key active components and core targets was verified using AutoDock software.

RESULTS

Total 42 active ingredients and 142 potential targets of Jiawei Jiaotai Pill were identified. There were 100 common targets between the DCM and Jiawei Jiaotai Pills. Through this screening process, TNF, IL6, TP53, EGFR, INS, and other important targets were identified. These targets are mainly involved in the positive regulation of the mitogen-activated protein kinase (MAPK) MAPK cascade, response to xenobiotic stimuli, response to hypoxia, positive regulation of gene expression, positive regulation of cell proliferation, negative regulation of the apoptotic process, and other biological processes. It was mainly enriched in the AGE-RAGE signaling pathway in diabetic complications, DCM, PI3K-Akt, interleukin-17, and MAPK signaling pathways. Molecular docking results showed that Jiawei Jiaotai Pill's active ingredients had good docking activity with DCM's core target.

CONCLUSION

The active components of Jiawei Jiaotai Pill may play a role in the treatment of DCM by reducing oxidative stress, cardiomyocyte apoptosis and fibrosis, and maintaining metabolic homeostasis.

Keywords: Jiawei Jiaotai pill; Diabetic cardiomyopathy; Mechanism of action; Enrichment analysis; Network pharmacology; Molecular docking

Core Tip:Jiawei Jiaotai Pill is composed of Rhizoma Coptidis, Cinnamon, Radix Astragali, and Puerariae Lobatae Radix. It is mainly used to treat disharmony between the heart and kidneys, insomnia, sore mouth, and the tongue. It is often used to improve apoptosis, increase insulin secretion, and improve blood sugar tolerance. However, there are no reports on the mechanism of Jiawei Jiaotai Pills in the treatment of diabetic cardiomyopathy. We used the network pharmacology method, starting from the drug target, focused on analyzing the biological processes and conducting enrichment analysis of the important targets, and used molecular docking technology to verify the results.